Arrowhead Pharma swings to Q2 loss as costs rise

Arrowhead Pharmaceuticals

07/05/2026 21:36

Corrects net loss to $132.7 mln, from $4.84 mln, in KD table

Overview

RNAi therapeutics developer's fiscal Q2 revenue fell and missed analyst expectations

Company posted a net loss for fiscal Q2, reversing a profit last year

Higher operating expenses driven by increased R&D and administrative costs

Outlook

Company entered exclusive worldwide license deal for ARO-PNPLA3 with Madrigal Pharmaceuticals, securing $25 mln upfront and eligibility for milestone payments

Result Drivers

REDEMPLO LAUNCH MOMENTUM - Co said it continued to build momentum for REDEMPLO in the U.S. following FDA approval, with total prescriptions received and in process exceeding 400 and new weekly prescriptions accelerating

INCREASED R&D ACTIVITY - Co highlighted initiation of new clinical trials and presentation of new data for pipeline programs, including obesity and cardiovascular candidates

Company press release: ID:nBwDpx5Ca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$73.74 mln
$79.99 mln (11 Analysts)
Q2 EPS
-$0.93
Q2 Net Income
-$132.7 mln
Q2 Operating Expenses
$215 mln
Q2 Operating Income
-$141.26 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $84.00, about 6.1% above its May 6 closing price of $79.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)